Abivax (ABVX) to Release Earnings on Monday

Abivax (NASDAQ:ABVX) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Abivax to post earnings of ($2.24) per share and revenue of $1.7950 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 23, 2026 at 7:00 AM ET.

Abivax Price Performance

Shares of NASDAQ ABVX opened at $120.34 on Friday. The business has a 50 day simple moving average of $119.35 and a 200-day simple moving average of $110.37. The company has a market capitalization of $9.52 billion, a price-to-earnings ratio of -28.79 and a beta of 1.00. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax has a twelve month low of $4.77 and a twelve month high of $148.83.

Institutional Trading of Abivax

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jump Financial LLC bought a new stake in Abivax in the 4th quarter valued at $872,000. Scientech Research LLC bought a new stake in Abivax in the 3rd quarter valued at about $789,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Abivax during the third quarter worth approximately $616,000. OLD Mission Capital LLC bought a new position in shares of Abivax during the fourth quarter worth approximately $513,000. Finally, Brooklyn Investment Group acquired a new stake in shares of Abivax in the fourth quarter valued at approximately $445,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ABVX. Oppenheimer set a $131.00 target price on shares of Abivax in a research report on Thursday, January 8th. Citigroup restated a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Morgan Stanley lifted their price objective on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Truist Financial set a $140.00 target price on Abivax in a report on Monday, November 24th. Finally, Citizens Jmp increased their price target on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $136.69.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.